Clinical Trials Snapshot

Study of LN-145 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Phase 2, prospective, multicenter, single-arm, open-label, interventional trial evaluating adoptive cell therapy with autologous tumor infiltrating lymphocyte infusion (LN-145) followed by IL-2 after a non-myeloablative lymphodepletion preparative regimen for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Head/Neck Cancer Scorecard

Phase 2, prospective, multicenter, single-arm, open-label, interventional trial evaluating adoptive cell therapy with autologous tumor infiltrating lymphocyte infusion (LN-145) followed by IL-2 after a non-myeloablative lymphodepletion preparative regimen for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Head/Neck Cancer Scorecard